Literature DB >> 16580884

Cognitive performance of patients with mesial temporal lobe epilepsy is not associated with human prion protein gene variant allele at codons 129 and 171.

Erica R Coimbra1, Karinne Rezek, Sara Escorsi-Rosset, Michele C Landemberger, Rosa M R P S Castro, Michelle N Valadão, Ricardo Guarnieri, Tonicarlo R Velasco, Vera C Terra-Bustamante, Marino M Bianchin, Lauro Wichert-Ana, Veriano Alexandre, Ricardo R Brentani, Vilma R Martins, Américo C Sakamoto, Roger Walz.   

Abstract

Cognitive impairment has long been recognized in people with medically refractory epilepsies. Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS), the most common surgically remediable epileptic syndrome, has been associated with a cellular prion protein (PrPc) gene (Prnp) variant allele at codon 171. The polymorphism consisting of a methionine-for-valine substitution at codon 129 has been associated with early cognitive deterioration in elderly people and patients with Down syndrome. The same variant allele in homozygosis (V129V) has been associated to a lower long-term memory in healthy humans. PrPc mediates several processes related to neuroplasticity, and its role in cognitive processes remains unknown. In this study, we evaluated the genetic contribution of Prnp alleles to cognitive performance in patients with MTLE-HS. Cognitive performance, measured with 19 neuropsychological tests, of patients with refractory MTLE-HS with the normal Prnp genotypes was compared with that of patients with the variant alleles at codons 129 and 171. With the effects of clinical, demographic, electrophysiological, and neuroimaging variable interactions controlled by multiple linear regression analysis and adjustment for multiple test comparisons, the presence of Prnp variant alleles was found not to be significantly associated to cognitive performance of patients with MTLE-HS. The presence of variant alleles at codons 129 and 171 is not associated to cognitive performance of patients with refractory MTLE-HS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580884     DOI: 10.1016/j.yebeh.2006.02.007

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  7 in total

1.  Prnp gene and cerebellum volume in patients with refractory mesial temporal lobe epilepsy.

Authors:  Michelle N Valadão; Erica R Coimbra; Michele C Landemberger; Tonicarlo R Velasco; Vera C Terra; Lauro Wichert-Ana; Veriano Alexandre; David Araújo; Ricardo Guarnieri; Vilma R Martins; Antônio Carlos Santos; Américo C Sakamoto; Roger Walz
Journal:  Neurol Sci       Date:  2013-10-05       Impact factor: 3.307

2.  The prion protein M129V polymorphism: longevity and cognitive impairment among Polish centenarians.

Authors:  Ewa Golanska; Monika Sieruta; Elizabeth Corder; Sylwia M Gresner; Anna Pfeffer; Malgorzata Chodakowska-Zebrowska; Tomasz M Sobow; Izabela Klich; Malgorzata Mossakowska; Aleksandra Szybinska; Maria Barcikowska; Pawel P Liberski
Journal:  Prion       Date:  2013-02-13       Impact factor: 3.931

Review 3.  Genetics of cognition in epilepsy.

Authors:  Robyn M Busch; Imad Najm; Bruce P Hermann; Charis Eng
Journal:  Epilepsy Behav       Date:  2014-06-25       Impact factor: 2.937

4.  Genetics of temporal lobe epilepsy: a review.

Authors:  Annick Salzmann; Alain Malafosse
Journal:  Epilepsy Res Treat       Date:  2012-02-19

5.  The decreased connectivity in middle temporal gyrus can be used as a potential neuroimaging biomarker for left temporal lobe epilepsy.

Authors:  Jinlong Wu; Jun Wu; Ruimin Guo; Linkang Chu; Jun Li; Sheng Zhang; Hongwei Ren
Journal:  Front Psychiatry       Date:  2022-08-10       Impact factor: 5.435

Review 6.  Molecular pathology of human prion diseases.

Authors:  Gabor G Kovacs; Herbert Budka
Journal:  Int J Mol Sci       Date:  2009-03-09       Impact factor: 5.923

Review 7.  Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases.

Authors:  Eva Bagyinszky; Vo Van Giau; Young Chul Youn; Seong Soo A An; SangYun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-14       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.